Actinic Keratosis Treatment Market

Market Overview

The global actinic keratosis treatment market size was valued at USD 6.42 billion in 2022. It is estimated to reach USD 9.22 billion by 2031, growing at a CAGR of 4.1% during the forecast period (2023–2031). The increase in the prevalence of actinic keratosis illness is projected, along with an increase in the usage of actinic keratosis topical treatment solutions, will drive the growth of the global market.

The aim of treating actinic keratosis, a skin condition caused by prolonged sun exposure, is to prevent the transformation of these precancerous lesions into skin cancer. Treatment options for actinic keratosis include topical medications, cryotherapy, curettage and electrodesiccation, photodynamic therapy (PDT), and laser treatment. Medications such as lotions or gels containing fluorouracil, imiquimod, ingenol mebutate, or diclofenac are applied to the affected area to target and eliminate abnormal cells. "Curettage" and "electrification" refer to removing injured skin with a curette and eliminating any remaining aberrant cells by electrically scorching the treated area.

In photodynamic therapy, a photosensitizing agent is applied to the affected area. After being activated by specific light wavelengths, the agent kills abnormal cells. In laser therapy, only the defective cells are targeted and eliminated. Variables include the patient's general health, the quantity and distribution of lesions, their thickness, and the recommended course of treatment. It is necessary to consult a dermatologist to determine the best course of action. Regular examinations and UV protection are essential for preventing the recurrence of actinic keratosis and lowering the risk of developing skin cancer.

Market Dynamics

Global Actinic Keratosis Treatment Market Drivers

Rise in Prevalence of Actinic Keratosis

An increase in the prevalence of actinic keratosis disease is anticipated to lead to increased demand for treatments that treat actinic keratosis. Actinic keratosis, for example, is the most frequent kind of precancer, and it affects more than 58 million people in the United States, according to the Skin Cancer Foundation.

In addition, an item that appeared in News Medical stated that the total rate of actinic keratosis in the United States is roughly 10.2% in females and 26.5% in males. This information was taken from a survey that was conducted. Therefore, an increase in the prevalence of actinic keratosis illness is projected, along with an increase in the usage of actinic keratosis topical treatment solutions. This will drive the growth of the global market.

Potential Drugs Present in the Pipeline

Because actinic keratosis is growing more prevalent, several pharmaceutical companies are researching the possibility of developing novel treatments for the condition. There are currently several pharmaceutical companies working on the invention of medications for the treatment of actinic keratosis, and there are currently a number of these actinic keratosis therapy treatments at various levels of the development process.

Actinic keratosis is a skin condition that is caused by exposure to the sun. Some prospective drugs currently developing are AM-001, GDC 695, SOR-007, SRT-100, Tirbanibulin, and Tuvatexib. It is projected that the presence of a wide variety of pharmaceuticals in the pipeline, including ideal treatments in the later stages of research, will fuel the expansion of the market. Specifically, this expansion will take place in the United States.

Global Actinic Keratosis Treatment Market Restraint

Availability of Alternate Treatment Options

The rough, scaly patch on the skin, characteristic of actinic keratosis (AK), is caused by prolonged exposure to ultraviolet radiation (UV) from the sun or indoor tanning beds. The most prevalent locations for its appearance are the face, lips, ears, backs of the hands and forearms, scalp, neck, and scalp. Although several medications, including fluorouracil, imiquimod, diclofenac, ingenol mebutate, and others, have been given the go-ahead to treat actinic keratosis, there is still no cure. Cryotherapy, photodynamic therapy, and combination therapy are some additional methods of treatment that can be utilized in treating actinic keratosis.

The expansion of the actinic keratosis market is hindered by factors such as the increased use of cryotherapy for treating actinic keratosis due to its cost-effectiveness and the rise in awareness of photodynamic therapy and scraping. Both of these factors are expected to continue. Therefore, an increase in consumer interest in alternative treatments may hinder the expansion of the market.

Global Actinic Keratosis Treatment Market Opportunities

Growth Opportunities in Emerging Markets

The availability of enhanced infrastructure in the pharmaceutical industry, an increase in the number of pharmaceutical businesses, and an increase in demand for actinic keratosis treatment products are projected to be the primary growth drivers for the actinic keratosis treatment market in the next years. This is expected to be driven by opportunities in emerging markets.

A major increase in the demand for superior sophisticated manufacturing systems and significant investments made by the government to improve healthcare infrastructure are driving significant growth in the healthcare business in emerging nations. This growth is occurring at a significant rate. The increased prevalence of actinic keratosis in countries such as Australia and New Zealand would allow this market to be expanded.

Regional Analysis

Based on region, the global actinic keratosis treatment market is bifurcated into North America, Europe, Asia-Pacific, and LAMEA.

North America Dominates the Global Market

North America is the most significant global actinic keratosis treatment market shareholder and is estimated to exhibit a CAGR of 3.4% over the forecast period. An increased incidence of actinic keratosis in the North American market is expanding as a result of factors including rising actinic keratosis treatment drug demand, the availability of high-tech healthcare facilities with skilled medical staff, and an increase in the number of R&D projects to create actinic keratosis therapies. For instance, the American Academy of Dermatology (AAD) reports that 60% of Americans who are 40 or older are likely to have at least one actinic keratosis lesion. Fair-skinned people frequently develop actinic keratosis, which is more common in places with much sun exposure.

Additionally, due to a higher frequency of actinic keratosis, the United States held the highest share of the global market for actinic keratosis treatments. According to several studies, the most frequent outpatient dermatologic procedure in the United States is the removal of actinic keratoses.

Europe is anticipated to exhibit a CAGR of 4.2% over the forecast period. The market for treating actinic keratosis in European nations is anticipated to expand steadily throughout the forecast period. The availability of sophisticated actinic keratosis treatment products and the rising demand for actinic keratosis treatment products impact the market's expansion in this area. Additionally, the expansion of the actinic keratosis patient population, a developed pharmaceutical industry infrastructure, and the accessibility of qualified specialists are the other major growth drivers in Europe.

Furthermore, actinic keratosis is most common in northern Europe, where 17% of people are affected completely. For instance, actinic keratosis is the reason for every third dermatologist appointment in some nations, including Germany. Actinic keratosis was the most popular dermatological condition in Germany, where the prevalence of the disorder has increased more rapidly than other dermatological conditions during the past ten years. According to a European guideline, actinic keratosis is becoming the most prevalent in situ carcinoma in humans, which affects millions of individuals globally.

The Asia-Pacific market, anticipated to grow quickly throughout the projected period, offers many promising possibilities for treating actinic keratosis. The condition's prevalence is rising in southern nations like Australia and New Zealand, and the region is becoming more aware of actinic keratosis treatment choices, which are all factors in the market expansion in this area. Asia-Pacific is anticipated to experience the fastest market growth during the forecast period due to the region's rising adoption of AK therapeutics, developing R&D sector, higher prevalence of AK in some countries like Australia and New Zealand, rapid healthcare reforms, and accessibility to treatment drugs. The increased attention that major manufacturers pay to expand their geographic reach in growing Asia-Pacific nations also presents the market expansion with good prospective chances.

LAMEA is studied in Brazil, Saudi Arabia, South Africa, and the remaining LAMEA countries. In LAMEA, the actinic keratosis treatment market is in its infancy due to a lack of pharmaceutical companies with advanced manufacturing facilities and trained professionals. Due to rising healthcare spending, the market for actinic keratosis treatments in LAMEA is anticipated to expand during the forecast period.

In addition, the growth of the LAMEA market is driven by an increase in government funding and the creation of healthcare awareness programs. LAMEA is an emerging market that is anticipated to provide lucrative growth opportunities for the key participants due to an increase in the target population, the demand for drugs used to treat actinic keratosis, and the improvement of healthcare infrastructure. In addition, the rising prevalence of actinic keratosis in LAMEA has fuelled the adoption of actinic keratosis treatment products, propelling the market growth.

Segmental Analysis

The global actinic keratosis treatment market is bifurcated into drug type, type, and distribution channel.

Based on drug type, the global market is bifurcated into fluorouracil, imiquimod, diclofenac, and others. 

The fluorouracil segment dominates the global market and is projected to exhibit a CAGR of 3.8% over the forecast period. The cream and solution form of 5-fluorouracil (5-FU) is one of the most frequently used for actinic keratosis treatments. It can be purchased under various brand names, including Caraco, Efudex, Fluor plex, and Tolak, amongst others. It can be obtained in various formulations, including a cream or solution of 5% concentration, a solution of 2% concentration, a cream or solution of 1% concentration, a micronized cream of 0.5% concentration, and others.

The most common application of this 5% cream for treating actinic keratosis involves using the cream twice a day for one month. Neoadjuvant therapy with fluorouracil 0.5% cream is typically administered before cryosurgery for optimal results. Several studies concluded that a one-week course of fluorouracil 0.5% can minimize the number of lesions that need to be removed by cryosurgery and lessen the likelihood that the condition will return.

Based on type, the global actinic keratosis treatment market is segmented into prescription and OTC. 

The prescription segment dominates the global market and is predicted to exhibit a CAGR of 4.3% during the forecast period. When dispensing a prescription drug or medicine, the law mandates that a valid medical prescription be shown. Getting medications through a doctor's prescription ensures that the patient takes the exact amount, minimizing the likelihood of unpleasant side effects. Ingenol mebutate, imiquimod, fluorouracil, methyl amino levulinate (MAL) or 5-aminolevulinic acid (5-ALA), and 5-aminolevulinic acid (5-ALA) are the prescription medications that are utilized the most frequently. Because prescription medications such as fluorouracil, ingenol mebutate, and imiquimod are preferred for treating actinic keratosis, the prescription sector was the primary revenue contributor, and this trend is anticipated to continue throughout the projection period.

Based on the distribution channel, the global market is bifurcated into hospital pharmacies, drug stores, retail pharmacies, and online providers. 

The hospital pharmacies segment owns the highest actinic keratosis treatment market share and is predicted to exhibit a CAGR of 4.3% over the forecast period. There is a special kind of pharmacy known as a hospital pharmacy, located inside a hospital and operates there. Inside hospitals can be found the pharmacies that serve those facilities. Hospital pharmacies are considered one of the subcategories of the wider pharmacy profession. The production of medications and medical equipment and their storage, compounding, and distribution are all components of this process.

In addition, the medical staff and the patients receive instructions on making safe and efficient use of the products. Some factors contributing to the growth of this market sector include an increase in the number of patients suffering from actinic keratosis, an increase in the number of hospital pharmacies, and an improvement in the organizational structure of hospital pharmacies in developing nations.

Recent Developments

• September 2022- PharmaEssentia Corporation received approval from Taiwan's Ministry of Health and Welfare (MOHW) for KX01 as the New Drug Application for Actinic Keratosis with the license number Wei-Bu-Yao-Shu-Zi No. 028364.
• May 2022- Actinic Keratosis Global Day was launched by Almirall in partnership with Euro melanoma and AEDV Fundación Piel Sana and coincided with Skin Cancer Awareness Month.